30results about How to "Subject is at risk" patented technology

Method and apparatus for the treatment of cardiac failure, Cheyne Stokes breathing or central sleep apnea are disclosed. A subject is provided with ventilatory support, for example positive pressure ventilatory support using a blower and mask. Respiratory airflow is determined. From the respiratory airflow are derived a measure of instantaneous ventilation (for example half the absolute value of the respiratory airflow) and a measure of longterm average ventilation (for example the instantaneous ventilation low pass filtered with a 100 second time constant). A target ventilation is taken as 95% of the longterm average ventilation. The instantaneous ventilation is fed as the input signal to a clipped integral controller, with the target ventilation as the reference signal. The output of the controller determines the degree of ventilatory support. Clipping is typically to between half and double the degree of support that would do all the respiratory work. A third measure of ventilation, for example instantaneous ventilation low pass filtered with a time constant of 5 seconds, is calculated. Ventilatory support is in phase with the subject's respiratory airflow to the fuzzy extent that this ventilation is above target, and at a preset rate conversely.

A method for identifying, suppressing, and reversing epileptogenesis, which is considered to be a learned response due to brain plasticity. The method includes identifying three epileptogenic conditions, neuronal hyperexcitability, spatial overconnectivity, and temporal overconnectivity. A treatment that accounts for each of these conditions is then be administered to the subject to reverse, or “unlearn,” epilepsy.

A method of identifying objects in a subject's ear, comprising the following steps: introducing an optical electronic imaging unit and a light source into an ear canal of a subject's outer ear, wherein the electronic imaging unit exhibits an optical axis directed in a distal direction, especially directed at the eardrum of the subject's ear; using the electronic imaging unit to capture an image from an eccentric observation point positioned on the optical axis and positioned eccentrically within the ear canal; and determining brightness or color information to identify objects shown in the image by electronic means, in order to automatically identify the objects, especially the eardrum.

The present invention relates to a poster holder (10,10′,10″,10′″,1000) comprising a support (3,3′,3″,3*, 3000) intended to be suspended on a wall and provided with at least one engagement seat (6, 600,6″,6*,6′″) and with a bar (4,4′,4″) comprising in turn a fixed length lower portion (18, 18′,18″) comprising a gripping device for engaging an edge of a poster (5) and at least one slider (11,11′,11″,11′″,1100) slidably associated to said lower portion (18, 18′,18″), said slider (11,11′,11″,11′″,1100) being insertable into said engagement seat (6, 600,6″,6*,6′″) such to make a connection between said support (3,3′,3″,3*) and said bar (4, 4′,4″).

Provided herein are proteomic biomarkers of spontaneous preterm birth, proteomic biomarkers of term birth, and methods of use thereof. In particular, provided are tools for determining whether a pregnant subject is at an increased risk for premature delivery, as well as tools for decreasing a pregnant subject's risk for premature delivery.

The invention discloses compounds of Formula (I),wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 μm to about 90 μm, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

Provided herein are reagents, methods and biochemical markers for identifying individuals with glucoregulatory dysfunction and providing therapeutic intervention for individuals identified as at risk for glucoregulatory dysfunction. Specifically provided herein are methods for identifying a subject with glucoregulatory dysfunction based on changes in fasting blood lipid concentrations including, inter alia, diacylglycerols.

Encoding element (100) at least selectively transparent to an infrared or ultraviolet light radiation, incident thereon on a first incidence surface (101), wherein—in the volume defined by said encoding element (100)—a plurality of areas (104) is provided, previously selected and arranged according to a predefined pattern wherein at least one polarisation characteristic of the optical radiation (200) that is incident thereon is varied, wherein the variation of said polarisation characteristic of said incident radiation is varied according to a localised alteration pattern biunivocally associated to a predefined ciphering key, and wherein said plurality of areas is arranged between said first incidence surface (101) on which said infrared or ultraviolet light radiation is incident in use, and a second output surface (102) of said infrared or ultraviolet light optical radiation.